Saudi Arabia suspends Avandia for Six Months

Saudi Arabia’s Saudi Food and Drug Authority (SFDA) has become the first healthcare regulator to suspend GlaxoSmithKline’s (GSK) controversial diabetes drug Avandia, citing that the drug’s potential risks outweigh its benefits. The SFDA decided this month that it will suspend Avandia, along with any detailing or advertising of the drug, for six months.

According to the SFDA, this decision is based on growing scientific evidence against Avandia, or rosiglitazone, which indicates that the drug can lead to severe cardiovascular risks, including heart attacks. The suspension is not permanent and will give GSK six months to provide reasons to keep the drug on the market and supply data that demonstrates Avandia’s safety.


Saudi Arabia says no to Avandia for six months


Return to Avandia News Menu